UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act 1934

Date of Report (Date of earliest event reported): September 4, 2012

 

 

Coronado Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   001-35366   20-5157386

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

15 New England Executive Park,

Burlington, MA

   01803
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 238-6621

(Former Name or Former Address, is Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01. Regulation FD Disclosures.

On September 5, 2012, executives of Coronado Biosciences, Inc. (the “Company”) will make a presentation about the Company to certain analysts and investors at the Stifel Niclolaus 2012 Healthcare Conference in Boston, Massachusetts. A copy of the slide presentation is furnished as exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    September 5, 2012 Slide Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORONADO BIOSCIENCES, INC.
    By:   /s/ Lucy Lu
      Name: Lucy Lu
      Title: Chief Financial Officer

Dated: September 4, 2012

EXHIBIT INDEX

 

Exhibit
No.

   

Description

99.1    September 5, 2012 Slide Presentation